Michiga subcutaneous injection 30 mg vial, manufactured by Maruho, contains nemolizumab (genetical recombination). This monoclonal antibody is approved in Japan for treating pruritus (itching) associated with moderate-to-severe atopic dermatitis in adults and children aged 13 and over, when existing treatments are insufficient. The 30mg 1 bottle formulation has a YJ code of 4490408D1021.
Michiga subcutaneous injection 30 mg vial
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →